N Anthony Coles insider trades: Cerevel Therapeutics Holdings (CERE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where N reports to the SEC
and 4 more companies
Open-market buys and sales
41 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 1, 2024 | CERE | ↓ Sell | 25,000 | $41.18 | $1.0M | Direct | Jul 3, 2024 (2d) |
| Jun 3, 2024 | CERE | ↓ Sell | 50,000 | $40.61 | $2.0M | Direct | Jun 5, 2024 (2d) |
| May 10, 2024 | CERE | ↓ Sell | 50,000 | $42.10 | $2.1M | Direct | May 14, 2024 (4d) |
| Apr 1, 2024 | CERE | ↓ Sell | 50,000 | $42.33 | $2.1M | Direct | Apr 3, 2024 (2d) |
| Mar 4, 2024 | CERE | ↓ Sell | 50,000 | $41.01 | $2.1M | Direct | Mar 6, 2024 (2d) |
| Feb 29, 2024 | CERE | ↓ Sell | 50,000 | $41.16 | $2.1M | Direct | Mar 4, 2024 (4d) |
| Feb 7, 2024 | CERE | ↓ Sell | 2,506 | $41.54 | $104K | Direct | Feb 8, 2024 (1d) |
| Jan 2, 2024 | CERE | ↓ Sell | 50,000 | $42.24 | $2.1M | Direct | Jan 4, 2024 (2d) |
| Nov 14, 2023 | CERE | ↓ Sell | 22,824 | $25.13 | $573K | Direct | Nov 16, 2023 (2d) |
| Nov 8, 2023 | CERE | ↓ Sell | 27,176 | $25.02 | $680K | Direct | Nov 9, 2023 (1d) |
| Nov 3, 2023 | CERE | ↓ Sell | 100,000 | $25.34 | $2.5M | Direct | Nov 6, 2023 (3d) |
| Sep 7, 2023 | CERE | ↓ Sell | 50,000 | $24.07 | $1.2M | Direct | Sep 8, 2023 (1d) |
| Jul 11, 2023 | CERE | ↓ Sell | 50,000 | $30.03 | $1.5M | Direct | Jul 13, 2023 (2d) |
| Jun 1, 2023 | CERE | ↓ Sell | 50,000 | $32.60 | $1.6M | Direct | Jun 5, 2023 (4d) |
| May 4, 2023 | CERE | ↓ Sell | 50,000 | $31.47 | $1.6M | Direct | May 8, 2023 (4d) |
| Apr 11, 2023 | CERE | ↓ Sell | 50,000 | $25.06 | $1.3M | Direct | Apr 13, 2023 (2d) |
| Mar 3, 2023 | CERE | ↓ Sell | 50,000 | $27.12 | $1.4M | Direct | Mar 6, 2023 (3d) |
| Feb 7, 2023 | CERE | ↓ Sell | 50,000 | $33.13 | $1.7M | Direct | Feb 8, 2023 (1d) |
| Jan 5, 2023 | CERE | ↓ Sell | 50,000 | $29.94 | $1.5M | Direct | Jan 6, 2023 (1d) |
| Dec 28, 2022 | REGN | ↓ Sell | 5,758 | $714.11 | $4.1M | Direct | Dec 30, 2022 (2d) |
| Dec 9, 2022 | CERE | ↓ Sell | 50,000 | $26.67 | $1.3M | Direct | Dec 13, 2022 (4d) |
| Sep 6, 2022 | REGN | ↓ Sell | 6,000 | $581.28 | $3.5M | Direct | Sep 8, 2022 (2d) |
| Sep 15, 2021 | REGN | ↓ Sell | 11,948 | $658.98 | $7.9M | Direct | Sep 17, 2021 (2d) |
| Aug 18, 2021 | REGN | ↓ Sell | 6,000 | $650.00 | $3.9M | Direct | Aug 19, 2021 (1d) |
| Aug 13, 2021 | REGN | ↓ Sell | 2,000 | $625.00 | $1.3M | Direct | Aug 16, 2021 (3d) |
| Aug 17, 2020 | MCK | ↓ Sell | 2,453 | $156.77 | $385K | Direct | Aug 19, 2020 (2d) |
| Aug 31, 2018 | MCK | ↓ Sell10b5-1 | 1,350 | $128.69 | $174K | Direct | Sep 4, 2018 (4d) |
| Jun 5, 2013 | ONXX | ↓ Sell10b5-1 | 6,562 | $90.00 | $591K | Direct | Jun 7, 2013 (2d) |
| Apr 3, 2013 | ONXX | ↓ Sell10b5-1 | 21,334 | $87.67 | $1.9M | Direct | Apr 3, 2013 (0d) |
| Mar 28, 2013 | ONXX | ↓ Sell10b5-1 | 10,938 | $90.00 | $984K | Direct | Apr 1, 2013 (4d) |
| Aug 8, 2012 | ONXX | ↓ Sell | 270,690 | $72.18 | $19.5M | Direct | Aug 9, 2012 (1d) |
| Aug 1, 2012 | ONXX | ↓ Sell10b5-1 | 8,820 | $74.37 | $656K | Direct | Aug 3, 2012 (2d) |
| Jul 25, 2012 | ONXX | ↓ Sell | 11,883 | $73.97 | $879K | Direct | Jul 27, 2012 (2d) |
| Jun 15, 2011 | ONXX | ↓ Sell10b5-1 | 8,845 | $36.10 | $319K | Direct | Jun 17, 2011 (2d) |
| Apr 1, 2011 | ONXX | ↓ Sell10b5-1 | 12,248 | $35.02 | $429K | Direct | Apr 4, 2011 (3d) |
| Dec 7, 2010 | ONXX | ↓ Sell10b5-1 | 13,669 | $32.00 | $437K | Direct | Dec 8, 2010 (1d) |
| Aug 19, 2010 | ONXX | ↓ Sell | 20,000 | $26.40 | $528K | Direct | Aug 19, 2010 (0d) |
| Apr 20, 2010 | ONXX | ↓ Sell10b5-1 | 1,576 | $29.95 | $47K | Direct | Apr 21, 2010 (1d) |
| Apr 1, 2010 | ONXX | ↓ Sell10b5-1 | 8,922 | $30.10 | $269K | Direct | Apr 2, 2010 (1d) |
| Apr 6, 2009 | ONXX | ↓ Sell10b5-1 | 7,500 | $27.31 | $205K | Direct | Apr 8, 2009 (2d) |
| Apr 1, 2009 | ONXX | ↓ Sell10b5-1 | 6,109 | $27.89 | $170K | Direct | Apr 2, 2009 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About N Anthony Coles's insider trades
N Anthony Coles is an insider at Cerevel Therapeutics Holdings (CERE). Since Apr 1, 2009, N has reported no open-market purchases and 41 sales worth $78.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
12 sales (8% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (55 filings), option exercises (33 filings), shares returned to the company (4 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CERE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.